1. Search Result
Search Result
Results for "

SHP

" in MedChemExpress (MCE) Product Catalog:

93

Inhibitors & Agonists

1

Fluorescent Dye

3

Peptides

2

Inhibitory Antibodies

9

Natural
Products

16

Recombinant Proteins

1

Isotope-Labeled Compounds

5

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121879
    SHP836
    1 Publications Verification

    SHP2 Phosphatase Cancer
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2 .
    SHP836
  • HY-114453

    SHP2 Phosphatase Others
    SHP389 is an allosteric SHP2 inhibitor, with an IC50 of 36 nM for both SHP2 and p-ERK .
    SHP389
  • HY-100388
    SHP099
    Maximum Cited Publications
    60 Publications Verification

    SHP2 Phosphatase Cancer
    SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 D61Y, SHP2E69K, SHP2 A72V, SHP2 E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth .
    SHP099
  • HY-145162
    SHP2-D26
    1 Publications Verification

    SHP2 PROTACs Phosphatase Cancer
    SHP2-D26 is a first, potent and effective SHP2 degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent .
    SHP2-D26
  • HY-115925

    SHP2 Phosphatase Cancer
    SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo .
    SHP2-IN-9
  • HY-125259

    SHP2 Phosphatase Cancer
    SHP504 is a SHP2 phosphatase inhibitor, with an IC50 of 21 μM for SHP2 1–525 .
    SHP504
  • HY-164427

    SHP2 ERK Cancer
    SHP2-IN-31 is a SHP2 inhibitor, with IC50s of 13 nM (Wild-type SHP2), >10000 nM (SHP1), >10000 nM (SHP2 E76K) . SHP2-IN-31 inhibits pERK in a panel of tumor cells. SHP2-IN-31 inhibits tumor growth in RTK/KRAS-driven xenograft models .
    SHP2-IN-31
  • HY-130631

    SHP2 Cancer
    SHP2-IN-5 (compound 1) is an inhibitor of SHP2 (IC50: 97 nM). SHP2 is a non-receptor protein tyrosine phosphatase associated with cell growth and proliferation. SHP2-IN-5 has the potential to inhibit cancer and SHP2-related human diseases .
    SHP2-IN-5
  • HY-162755

    SHP2 Apoptosis Cancer
    SHP2-IN-30 (compound 14i) is an allosteric SHP2 inhibitor with an IC50 of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase .
    SHP2-IN-30
  • HY-144396

    SHP2 Phosphatase Akt Apoptosis Cancer
    SHP2-IN-8 is a highly potent, selective, and cellularly active allosteric SHP2 inhibitor with IC50 value of 23 nM and Ki of 22 nM. SHP2-IN-8 is reversible and noncompetitive. SHP2-IN-8 causes a significant thermal shift with the ΔTm of 7.01 ℃. SHP2-IN-8 induces the apoptosis and inhibits the phosphorylation of AKT in Hela cells .
    SHP2-IN-8
  • HY-149241

    SHP2 Cancer
    SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.
    SHP2-IN-13
  • HY-155272

    SHP2 Cancer
    SHP2-IN-16 (compound 222) is a SHP2 inhibitor with an IC50 value of 1 nM. SHP2-IN-16 can be used for glioblastoma research .
    SHP2-IN-16
  • HY-155273

    SHP2 Cancer
    SHP2-IN-17 (compound 192) is a SHP2 inhibitor with an IC50 value of 2 nM. SHP2-IN-17 can be used for glioblastoma research .
    SHP2-IN-17
  • HY-155274

    SHP2 Cancer
    SHP2-IN-18 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-18 can be used for glioblastoma research .
    SHP2-IN-18
  • HY-155275

    SHP2 Cancer
    SHP2-IN-19 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-19 can be used for glioblastoma research .
    SHP2-IN-19
  • HY-155276

    SHP2 Cancer
    SHP2-IN-20 (compound 193) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-20 can be used for glioblastoma research .
    SHP2-IN-20
  • HY-155277

    SHP2 Cancer
    SHP2-IN-21 (compound 208) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-21 can be used for glioblastoma research .
    SHP2-IN-21
  • HY-162233

    SHP2 Phosphatase Cancer
    SHP2-IN-25 (Compound 6) is a SHP2 allosteric inhibitor, with an IC50 of 225 nM. SHP2-IN-25 can be used for the research of cancer .
    SHP2-IN-25
  • HY-157888

    SHP2 Phosphatase Cancer
    SHP2-IN-26 (Compound 4b) is a highly selective SHP2 allosteric inhibitor with a IC50 value of 3.2 nM. SHP2-IN-26 inhibits the phosphorylation of ERK and AKT in NCI-H358 cells. SHP2-IN-26 has antitumor activity .
    SHP2-IN-26
  • HY-114397
    SHP394
    1 Publications Verification

    SHP2 Phosphatase Cancer
    SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM .
    SHP394
  • HY-162476

    SHP2 Cancer
    SHP2-IN-28 (Compound 7188-0011) is an inhibitor of SHP2 (IC50=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity .
    SHP2-IN-28
  • HY-125260

    SHP2 Cancer
    SHP844 is a SHP2 inhibitor with the IC50 of 18.9 µM. SHP2 is a protein tyrosine phosphatase (PTP) that regulates tyrosine phosphorylation levels and is involved in cell proliferation, differentiation and survival .
    SHP844
  • HY-169111

    SHP2 Cancer
    SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity .
    SHP2-IN-32
  • HY-149607

    SHP2 Cancer
    SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .
    SHP2-IN-22
  • HY-D2204

    Phosphatase Fluorescent Dye Cancer
    SHP1-IN-1 (compound 5p) is a fluorescent probe for the protein tyrosine phosphatase SHP1 containing the Src homology 2 domain. SHP1-IN-1 has SHP1 inhibitory activity, selectivity for Fe 3+ ions and good fluorescence properties. SHP1-IN-1 exhibits aggregation post-quenching (ACQ) effect, good interference immunity and low detection limit (5.55 μM) .
    SHP1-IN-1
  • HY-114460

    SHP2 Phosphatase Others
    SHP2-IN-1 (compound 13) is an allergic inhibitor of SHP2 (PTPN11), with an IC50 of 3 nM.
    SHP2-IN-1
  • HY-149759

    SHP2 ERK Cancer
    SHP2-IN-23 (compound 30) is an orally active SHP2 inhibitor (IC50=38 nM) with excellent in vivo efficacy and pharmacokinetic profiles. SHP2-IN-23 inhibits ERK phosphorylation with IC50=5 nM .
    SHP2-IN-23
  • HY-145703

    SHP2 PROTACs Phosphatase Cancer
    SHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells .
    SHP2 protein degrader-2
  • HY-151464

    SHP2 Phosphatase HDAC Inflammation/Immunology Cancer
    SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch .
    SHP2/HDAC-IN-1
  • HY-N12915

    SHP2 Phosphatase Metabolic Disease Cancer
    SHP2-IN-29 (Compound 3) is a potent SHP2 inhibitor with an IC50 value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC50 values of 4.27 and 4.74 μM, respectively.
    SHP2-IN-29
  • HY-100388A
    SHP099 monohydrochloride
    Maximum Cited Publications
    60 Publications Verification

    SHP2 Phosphatase Cancer
    SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM .
    SHP099 monohydrochloride
  • HY-145159

    SHP2 PROTACs Phosphatase Apoptosis Cancer
    SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for researching SHP2 related diseases .
    SHP2 protein degrader-1
  • HY-153699

    SHP2 Cancer
    SHP2-IN-14 (compound 27) is an orally active and potent SHP2 allosteric inhibitor (IC50=7 nM) with anti-tumor activity. SHP2-IN-14 inhibits tumor progression in NCI-H358 tumor bearing mice, exhibits good pharmacokinetic characteristics and safty .
    SHP2-IN-14
  • HY-157535

    SHP2 Cancer
    SHP2-IN-24 (compound 111675) is a potent SHP2 inhibitor with an IC50 value of 0.878 µM and a Ki value of 0.118 µM .
    SHP2-IN-24
  • HY-162355

    SHP2 Cancer
    SHP2-IN-27 (compound 28) is an allosteric inhibitor of tyrosine phosphatase SH2 .
    SHP2-IN-27
  • HY-100365

    SHP-141

    HDAC Cancer
    Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma .
    Remetinostat
  • HY-125257

    LY6

    SHP2 Phosphatase Cancer
    SHP2 inhibitor LY6 (LY6) is potent and selective inhibitor of SHP2, with an IC50 of 9.8 µM. SHP2 inhibitor LY6 can inhibits SHP2-mediated cell signaling and proliferation .
    SHP2 inhibitor LY6
  • HY-150609

    SHP2 Phosphatase CDK Cancer
    SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .
    SHP2/CDK4-IN-1
  • HY-131132

    SHP2-IN-6

    SHP2 Phosphatase Cancer
    JAB-3068 (SHP2-IN-6) is a potent SHP2 inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC50 of 25.8 nM .
    JAB-3068
  • HY-131132A

    SHP2-IN-6 hydrochloride

    SHP2 Phosphatase Cancer
    JAB-3068 (SHP2-IN-6) hydrochloride is a potent SHP2 inhibitor with an IC50 of 25.8 nM. JAB-3068 hydrochloride is extracted from patent WO2017211303A1, compound 7 .
    JAB-3068 hydrochloride
  • HY-101190

    SHP626; LUM002

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .
    Volixibat
  • HY-P99110

    SHP643; DX-2930

    Kallikrein Inflammation/Immunology
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
    Lanadelumab
  • HY-16747

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
    Maralixibat chloride
  • HY-141523

    RMC-4630; SHP2-IN-7

    SHP2 Phosphatase Cancer
    Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice .
    Vociprotafib
  • HY-146561

    Glucocorticoid Receptor NF-κB Inflammation/Immunology
    S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC50 value of 1.92 μM for NF-κB transrepression (TR). S-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. S-HP210 is nontoxic at effective doses against mouse fibroblasts 3T3 cells .
    S-HP210
  • HY-19344
    Lifitegrast
    4 Publications Verification

    SAR 1118; SHP-606

    Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast
  • HY-19344A
    Lifitegrast sodium
    4 Publications Verification

    SAR 1118 sodium; SHP-606 sodium

    Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .
    Lifitegrast sodium
  • HY-123914

    Bacterial Infection
    P516-0475 is an uncompetitive inhibitor against endopeptidase PepO. P516-0475 is also an agonist of the Rgg2/3 system with antibacterial activity. P516-0475 induces expression of Rgg2/3-regulated genes in the presence of short hydrophobic pheromone (SHP) for activity and leads to positive modulation of lysozyme resistance .
    P516-0475
  • HY-100463
    TPI-1
    10+ Cited Publications

    Phosphatase Inflammation/Immunology Cancer
    TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor; inhibits recombinant SHP-1 with an IC50 of 40 nM.
    TPI-1
  • HY-125108
    PHPS1 sodium
    2 Publications Verification

    SHP2 Phosphatase Cardiovascular Disease Cancer
    PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .
    PHPS1 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: